HC Wainwright Has Optimistic Outlook of CORT Q3 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Corcept Therapeutics in a report issued on Monday, May 4th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.24. HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q3 2027 earnings at $0.85 EPS and Q4 2027 earnings at $0.84 EPS.

A number of other brokerages have also issued reports on CORT. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday, March 26th. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Piper Sandler raised their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.67.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $51.60 on Tuesday. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $91.00. The firm has a market capitalization of $5.54 billion, a P/E ratio of 147.43 and a beta of 0.36. The stock has a 50 day moving average price of $39.14 and a 200 day moving average price of $54.36.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. During the same period in the prior year, the business posted $0.17 earnings per share. Corcept Therapeutics’s revenue was up 4.9% on a year-over-year basis.

Insiders Place Their Bets

In other news, Director G Leonard Baker, Jr. acquired 100,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, March 17th. The shares were bought at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total value of $819,400.00. Following the transaction, the insider owned 2,231 shares in the company, valued at $91,404.07. The trade was a 89.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 66,198 shares of company stock worth $2,851,169 in the last ninety days. 20.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in shares of Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after acquiring an additional 587,053 shares during the period. Brown Capital Management LLC purchased a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $19,950,000. Allspring Global Investments Holdings LLC increased its holdings in shares of Corcept Therapeutics by 111.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 507,967 shares of the biotechnology company’s stock valued at $19,404,000 after acquiring an additional 268,155 shares during the period. First Trust Advisors LP increased its holdings in shares of Corcept Therapeutics by 34.1% in the 3rd quarter. First Trust Advisors LP now owns 720,224 shares of the biotechnology company’s stock valued at $59,858,000 after acquiring an additional 183,038 shares during the period. Finally, Public Sector Pension Investment Board increased its holdings in shares of Corcept Therapeutics by 13.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 365,838 shares of the biotechnology company’s stock valued at $30,405,000 after acquiring an additional 44,070 shares during the period. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.